TrovaGene Inc  

(Public, NASDAQ:TROV)   Watch this stock  
Find more results for trov
-0.178 (-41.31%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.24 - 0.26
52 week 0.24 - 2.85
Open 0.25
Vol / Avg. 12.99M/780,473.00
Mkt cap 9.63M
P/E     -
Div/yield     -
EPS -0.98
Shares 38.11M
Beta 0.35
Inst. own 19%
Mar 13, 2018
Q4 2017 Trovagene Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Nov 9, 2017
Q3 2017 Trovagene Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -3480.07% -10287.80%
Operating margin -4700.90% -10534.97%
EBITD margin - -10046.87%
Return on average assets -138.95% -67.95%
Return on average equity -462.46% -114.59%
Employees 53 -
CDP Score - -


11055 Flintkote Ave
SAN DIEGO, CA 92121-1220
United States - Map
+1-858-2175420 (Phone)
+1-858-2174768 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers. PCM-075 developed high selectivity to PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to other PLK inhibitors. PCM-075 has completed a safety study in patients with advanced metastatic solid tumors with a phase Ib/II clinical trial in patients with AML underway.

Officers and directors

Thomas H. Adams Jr. Ph.D. Chairman of the Board
Age: 74
Bio & Compensation  - Reuters
William J. Welch Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Athena M. Countouriotis M.D. Director
Age: 45
Bio & Compensation  - Reuters
Paul R. Billings M.D. Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
John P. Brancaccio CPA Independent Director
Age: 69
Bio & Compensation  - Reuters
Gary S. Jacob Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Rodney S. Markin M.D., Ph.D. Independent Director
Age: 58
Bio & Compensation  - Reuters